Cv carlos dujovne md

Internist,Basic & Clinical Pharmacologist,Clinical Lipidologist,
Clinical trials’Investigator Phases I-IV, R&D of drugs-nutraceuticals for prevention and treatment of Cardio-metabolic risks.
1998- PresentChairman and Medical Director, Kansas Foundation for Clinical Pharmacology Present
and Therapeutics (KFCPT
2008-(Sept.) 2013 Professor of Medicine, Division of Cardiovascular Medicine. Director ClinicalCardiovascular-Metabolic Risk Treatment Programs of Oregon Health & ScienceUniversity.
Clinical Trials Investigator Lipid, Heart Disease, Stroke Prevention, Weight Control, and Cardio-metabolic Diseases Risk Prevention and Treatment Programs 1998-2005 Medical Director and Principal Investigator, Radiant Research, Kansas City 1970-97 Professor of Medicine and of Pharmacology, University of Kansas 1975-97 Director of the Lipid, Arteriosclerosis and Metabolic Prevention Clinic - Kansas University Medical Center, Department of Medicine, Division of Clinical Pharmacology 1968-70 Johns Hopkins University School of Medicine, Baltimore, MD, Department of Medicine, Division of Clinical Pharmacology, Clinical Pharmacology Fellowship 1966-68 George Washington and Georgetown Universities, Washington, DC, 3rd YearResident (Internal Medicine), Hepatology and Gastroenterology Fellowship 1963-66 Chicago Medical School, Chicago, IL, Intern, First and Second Year Resident 1962-63 Buenos Aires University School of Medicine, Argentina, Instructor in Pharmacology and Medicine1961 Medical Doctorate Degree, Buenos Aires Univ. School of Medicine, Argentina CERTIFICATIONS
1962: ECFMG,
1963: Licensed, Illinois Board of Medical Education,
1965: Certified, Kansas State Board of Healing Arts,
1972: Eligible for the following Board Certifications: Internal Medicine,
1966; Gastroenterology, 1968; Clinical Pharmacology,
1998: Clinical Lipidology
2008: Oregon Board of Medical Examiners: MD150049.
1972-74 Recipient of the Faculty Development Award from the Pharmaceutical Manufacturer's
Association Foundation
1989 Merit Award for Excellence in performance as a faculty member, University of Kansas Medical Center MEMBERSHIPS
Founder Member of Board of Director National Lipid Association American Diabetes Association
Professional Section
American Federation for Clinical Research
American Heart Association, Arteriosclerosis Council
American Institute of Nutrition
American Medical Association
American Society for Clinical Nutrition
American Society for Clinical Pharmacology and Therapeutics American Society for Pharmacology
and Experimental Therapeutics Argentine American Medical Society
Association Mexicana para la Prevención de la Arteriosclerosis y sus Complicaciones (AMPAC)
Central Society for Clinical Research
Council on Nutrition, Metabolism, and Physical Activity – Charter Member
International Association for the Study of Liver Disease
International Union of Pharmacology International Union of Toxicology
National Lipid Association
Society for Experimental Biology and Medicine
American Society of Nutrition and Dietetics
Founder, Member Board of Directors, National Lipid Association.
American Society for Clinical Pharmacology and Therapeutics (1986-1988) - Chairman,
Government Affairs and Drug Regulation Committee
Inter-American Society of Clinical Pharmacology and Therapeutics - Member of the
International Advisory Committee
Drugs Affecting Lipid Metabolism (DALM) International Advisory Board
International Society of Clinical Pharmacology and Therapeutics - Member of Advisory Board
National Institutes of Health (NIH)
Reviewer Study Section, Grant Applications for Patient Oriented Research
Food and Drug Administration
Advisory Review Committee Study on the Effects of Simvastatin on COPD’s Morbidity and Mortality
Pharmaceutical Development Consultant: Hoffmann-LaRoche, Glaxo Wellcome, Bristol-Myers
Squibb, Hoechst Marion Roussel/Aventis, Merck & Co., American Cyanamid, Sterling-Winthrop,
Lederle, American Home Products, Rhône-Poulenc Rorer, Sandoz, Pfizer, Schering-Plough, Pfizer,
Sankyo, Sanofi, Berlex and Abbott.
Sporadic Consultantship: Food and Drug Administration; Veterans Administration Law Firms: On
litigation involving therapeutic medical practice, effect of drugs or
environmental or industrial toxicology matters.
Professional Nutrition Systems, Clinical Nutrition Research and Clinical Trials Consultant Clinical
Research Consultant, Humana Heart Institute International, Louisville, Kentucky (1991-1994)
Expert Consultant/Witness , Lawyers needs for litigations on Medical/Professional Malpractice
Annals of Internal Medicine
J. American Medical Association
AMA Drug Evaluations
Toxicology and Applied Pharmacology
The Medical Letter
J. Laboratory and Clinical Medicine
Pharmacology and Therapeutics
Life Sciences
Pharmaceutical Research
Lipid Digest
Expert Opinion on Investigational Drugs
Editorial Board of Reviewers, Journal of Clinical Lipidology
J. American Association for Clinical Chemistry
Archives of Internal Medicine
J. Clinical Pharmacology & Therapeutics Biochemical Pharmacology
Cardiovascular Pharmacology
Clinical e Investigation en Arteriosclerosis
American J. Medical Sciences
American J. Medicine
American Journal of CardiologyFuture Lipidology, Editorial Advisory Board PUBLICATIONS IN JOURNALS
Dujovne, C.A., Chan, C.H. and Zimmerman, H.J.: "Sulfonamide Hepatic Injury." Review of the literature and report of a case due to sulfamethoxazole." NEJM, 277:785-788, 1967. Zimmerman, H.J., Dujovne, C.A. and Levy, R.: "The Correlation of Serum Levels of Two Transaminases with Tissue Levels in Six Vertebrate Species." Comp Biochem Physiol, 25:1081-1089, 1968. Dujovne, C.A., Levy, R. and Zimmerman, H.J.: "Hepatotoxicity of Phenothiazines In Vitro as Measured by Loss of Aminotransferases to Surrounding Media." Proc Soc Exptl Biol Med, 128:561-563, 1968. Dujovne, C.A., Levy, R. and Zimmerman, H.J.: "The Correlation Between Serum and Tissue Levels of Enzymes in Six Vertebrate Species - Studies on Lactate Dehydrogenase, Phosphohexose Isomerase, Aldolase and Malate Dehydrogenase." Comp Biochem Physiol, 28:1193-1198, 1969. Weiss, P., Hersey, R.M., Dujovne, C.A. and Bianchine, J.R.: "The Metabolism of Amiloride Hydrochloride in Man." Clin Pharmacol Ther, 10:401-406, 1969. Dujovne, C.A. and Zimmerman, H.J.: "Cytotoxicity of Phenothiazines on Chang Liver Cells as Measured by Enzyme Leakage." Proc Soc Exptl Biol Med, 131:583-587, 1969. Weiss, P., Dujovne, C.A., Margolis, S., Lasagna, L. and Bianchine, J.R.: "Effects of SU-13437 on Serum Lipids in Hyperlipoproteinemic Patients." Clin Pharmacol Ther, 11(1):90-96, 1970. Dujovne, C.A., Lavelle, G., Weiss, P., Bianchine, J.R. and Lasagna, L.: "Toxicity of Hepatotoxic Drugs on Mouse Liver Tissue Culture." Arch Int Pharmacodyn Thér, 186(1):84-93, 1970. Calimlim, L.R., Dujovne, C.A., Morgan, J.P., Lasagna, L, and Bianchine, J.R.: "L-Dopa Treatment Failure: Explanation and Correction." Br Med J, 4(727):93-94, 1970. 10. Dujovne, C.A. and Strauss, H.W.: "Changes in Liver and Spleen Scans of Patients During Treatment with Two Hypolipidemic Drugs." Radiology, 98(3):682-684, 1971. 11. Dujovne, C.A., Weiss, P. and Bianchine, J.R.: "Comparative Clinical Therapeutic Trial with Two Hypolipidemic Drugs: Clofibrate and Nafenopin (SU-13437)." Clin Pharmacol Ther, 12(1):117-125, 1971. 12. Rivera-Calimlim, L., Morgan, J.P., Dujovne, C.A., Bianchine, J.R. and Lasagna, L.: "L- 3,4- Dihydroxyphenylalanine Metabolism by the Gut In Vitro." Biochem Pharm, 20:3051- 3057, 1971. 13. Bianchine, J.R., Calimlim, L.R., Morgan, J.P., Dujovne, C.A. and Lasagna, L.: "Metabo- lism and Absorption of L-3, 4 Dihydroxyphenylalanine in Patients with Parkinson's Disease." Ann NY Acad Sci, 179:126-140, 1971. 15. Clark, R.L., Kuhn, J.P. and Dujovne, C.A.: "Absence of Rickets After Chronic Dilantin Administration: Experimental Radiological Observations in Rats." Invest Radiol, 6(2):152-154, 1971. 16. Calimlim, L.R., Dujovne, C.A., Morgan, J.P., Lasagna, L. and Bianchine, J.R.: "Absorp- tion and Metabolism of L-Dopa by the Human Stomach." Europ J Clin Invest, 1:313-320, 1971. 17. Boulos, B.M., Dujovne, C.A. and Azarnoff, D.L.: "Tumors Potentiating Catecholamine-Induced Hypertension." Life Sci, 10(1):601-605, 1971. 18. Calimlim, L.R., Morgan, J.P., Dujovne, C.A., Bianchine, J.R. and Lasagna, L.: "L-3,4 Dihydroxyphenylalanine Metabolism by the Gut In Vitro." Biochem Pharmacol, 20:3051-3057, 1971. 19. Dujovne, C.A., Shoeman, D., Bianchine, J.R. and Lasagna, L.: "Experimental Bases for the Different Hepatotoxicity of Erythromycin Preparations in Man." J Lab Clin Med, 79(5):832-844, 1972. 20. Dujovne, C.A. and Shoeman, D.W.: "Toxicity of a Hepatotoxic Laxative Preparation in Tissue Culture and Excretion in Bile in Man." Clin Pharmacol Ther, 13(4):602-608, 1972. 21. Dujovne, C.A. and Azarnoff, D.L.: "Clinical Complications of Corticosteroid Therapy." A selected review. Med Clin North Am, 57(5):1331-1342, 1973. 22. Dujovne, C.A., Hurwitz, A., Kauffman, R.E. and Azarnoff, D.L.: "Colestipol and Clofibrate in Hypercholesterolemia." Clin Pharmacol Ther, 16(2):291-296, 1974. 23. Dujovne, C.A.: "Drug Hepatotoxicity in Medical Practice." Cont Ed for the Family Physician, 48-52, 24. Dujovne, C.A., Goto, Y. and Shoeman, D.W.: "Comparative Toxicity of General Anes- thetics on Chang Liver Cell Cultures." Diseases of the Liver and Biliary Tract, 5th Quadr. meetings, Int. Assoc. Study of the Liver, Acapulco, 1974, pp.48-51 (Karger, Basel, 1976). 25. Dujovne, C.A.: "Liver Cell Culture Toxicity and Surfactant Potency of Erythromycin Derivatives." Toxicol and Appl Pharmacol, 32:11-30, 1975. 26. Pentikäinen, P.J., Pentikäinen, L.A., Azarnoff, D.L. and Dujovne, C.A.: "Plasma Levels and Excretion of Estrogens in Urine in Chronic Liver Disease." Gastroenterology, 69:20-27, 1975. 27. Goto, Y., Dujovne, C.A., Shoeman, D.W. and Arakawa, K.: "Hepatotoxicity of General Anesthetics on Rat Hepatoma Cells in Culture." Proc Soc Exptl Biol Med, 151:789-794, 1976. 28. Goto, Y., Dujovne, C.A., Shoeman, D.W. and Arakawa, K.: "Liver Cell Culture Toxicity of General Anesthetics." Toxicol Appl Pharmacol, 36:121-130, 1976. 29. Dujovne, C.A., Azarnoff, D.L., Huffman, D.H., Pentikäinen, P., Hurwitz, A. and Shoeman, D.W.: "One-year Trials with Halofenate, Clofibrate, and Placebo." Clin Pharmacol Ther, 19(3):352-359, 1976. 30. Huffman, D.H., Azarnoff, D.L., Shoeman, D.W. and Dujovne, C.A.: "The Interaction Between Halofenate and Propranolol." Clin Pharmacol Ther, 19(6):807-812, 1976. 31. Dujovne, C.A.: "Experimental Investigations on the Different Hepatotoxic Potential of Erythromycin Derivatives." Méd Chir Dig, 5:365-367, 1976. 32. Dujovne, C.A., Azarnoff, D.L., Pentikäinen, P., Manion, C., Hurwitz, A. and Hassanein, K.: "A Two-year Crossover Therapeutic Trial with Halofenate and Clofibrate." Am J Med Sci, 272(3):277-284, 1976. 33. Huffman, D.H. and Dujovne, C.A.: "The Instability of Isoniazid and Acetylisoniazid in Frozen Plasma." Res Comm Chem Path Pharmacol, 15(1):203-204, 1976. 34. Dujovne, C.A.: "A Clinical Pharmacologist's View of Drug Hepatotoxicity." Pharmacol Res Comm, 35. Dujovne, C.A.: "Hepatotoxic and Cellular Uptake Interactions Among Surface Active Components of Erythromycin Preparations." Biochem Pharmacol, 27:1925-1930, 1978. 36. Carruthers, G. and Dujovne, C.A.: "Digoxin Therapy During T-tube Biliary Drainage in Man." 37. Salhab, A.S., Nooh, N.G. and Dujovne, C.A.: "Hepatocyte Responses to Volatile Anesthetics: Changes in Surface Scanning and Enzyme Leakage." Anesth Analg, 57:605-609, 1978. 38. Yasuhara, H., Dujovne, C.A., Ueda, I. and Arakawa, K.: "Hepatotoxicity and Surface Activity of Tricyclic Antidepressants In Vitro." Toxicol Appl Pharmacol, 47:47-54, 1979. 39. Yasuhara, H., Dujovne, C.A. and Ueda, I.: "Relationship between Surface Activity and Toxicity to Chang Liver Cultures of Tricyclic Antidepressants." Pharmacology, 18:95-102, 1979. 40. Dujovne, C.A., Azarnoff, D.L., Pentikainen, P., Manion, C. and Hurwitz, A.: "A Comparative Trial of Clofibrate and Nicotinyl Alcohol Tartrate in Hyperlipoproteinemic Patients." Am J Med Sci, 277(3):255-261, 1979. 41. Salhab, A.S., Yasuhara, H. and Dujovne, C.A.: "Surface Activity, Cellular Uptake and Cytotoxicity of Tricyclic Psychoactive Drugs In Vitro." Biochem Pharmacol, 28:1713-1718, 1979. 42. Cathcart-Rake, W.F. and Dujovne, C.A.: "Treatment of Hyperlipoproteinemias." Rational Drug 43. Hladik, W.B. and Dujovne, C.A.: "One Hundred Digitalis Blood Levels: A Utilization Review." Europ J Clin Pharmacol, 15:411-415, 1979. 44. Salhab, A.S. and Dujovne, C.A.: "Chlorpromazine Uptake by Isolated Rat Hepato- cytes." Proc Soc Exptl Biol Med, 161:270-274, 1979. 45. Salhab, A.S. and Dujovne, C.A.: "Interaction of Mestranol with Taurocholate Uptake by Isolated Rat Hepatocytes." Res Comm Chem Path Pharmacol, 26(a):297-307, Nov. 1979. 46. Carruthers, S.G. and Dujovne, C.A.: "Cholestyramine and Spironolactone and Their Combination in Digitoxin Elimination." Clin Pharmacol Ther, 27(2):184-187, 1980. 47. Dujovne, C.A. and Salhab, A.S.: "Erythromycin Estolate vs. Erythromycin Base, Surface Excess Properties and Surface Scanning Changes in Isolated Liver Cell Systems." Pharmacol, 20:285-291, 1980. 48. Beal, D., Dujovne, C.A. and Gillis, J.S.: "The Effect of Methyldopa on Human Judgment in Hypertensive Patients and Normal Volunteers." Res Comm in Psychology, Psychiatry and Behavior, 5(2):205-217, 1980. 49. Dujovne, C.A., Gustafson, J.H. and Dickey, R.A.: "Quantitation of Biliary Excretion of Drugs in Man." Clin Pharmacol Ther, 31(2):187-194, 1982. 50. Dujovne, C.A.: "Pitfalls in the Adequate Control of Hypolipidemic Drug Trials." Interamerican Cong of Clin Pharm & Ther, Caracas, Venezuela, pp 93-103, Oct. 10-15, 1982. 51. Dujovne, C.A., Pitterman, A., Vincek, W.C., Dorbrinska, M.R., Davies, R.O. and Duggan,D.E.: "Enterohepatic Circulation of Sulindac and Metabolites." Clin Pharmacol Ther, 33(2):172-177, 1983. 52. Zucker, M.L., Woodroof, J., Krehbiel, P., DeCoursey, S., Jackson, B. and Dujovne, C.A.: "The Effect of Variable Fat Diets and Cholesterol Lowering Drugs on Antithrombin III Levels in Hyperlipoproteinemic and Normal Subjects." Thrombosis Research, 30:661-669, 1983. 53. Dujovne, C.A.: "Guidelines for Diagnosing and Treating High-Risk Coronary Patients with Dyslipidemia." Res Staff Phys, Problems in Primary Care, 1-5, Feb. 1984. 54. Salhab, A.S., Stacey, N.H. and Dujovne, C.A.: "Prevention of Toxicity to Isolated Hepatocytes by Liposome Entrapment of Chenodeoxycholic Acid." Toxicol Letters, 21(1): 9-14, Apr. 1984. 55. Dujovne, C.A., Krehbiel, P., DeCoursey, S., Jackson, B., Chernoff, S., Pitterman, A. and Garty, M.: "Probucol with Colestipol in the Treatment of Hypercholesterolemia." Ann Intern Med, 100(4): 477-482, Apr. 4, 1984. 56. Dujovne, C.A., Chernoff, S., Krehbiel, P., Jackson, B., DeCoursey, S. and Taylor, H.: "Low Dose Colestipol Plus Probucol for Hypercholesterolemia." Am J Cardiol, 53:1514-1518, June 1, 1984. 57. Dujovne, C.A. and Block, J.E.: "Drug Treatment of Hyperlipidemia." Rational Drug Therapy, 18(6): 58. Dujovne, C.A., DeCoursey, S., Krehbiel, P., Jackson, B. and Chernoff, S.: "Serum Lipids in Normo- and Hyperlipidemics After Methyldopa and Propranolol." Clin Pharmacol Ther, 36:157-162, Aug. 1984. 59. Dujovne, C.A.: "The High-Risk Coronary Patient with Dyslipidemia: A Guide to Diagnosis and Therapy." J Fam Med, pp. 8-15, August 1984. 60. Dujovne, C.A., Atkins, F., Wong, B., DeCoursey, S., Krehbiel, P. and Chernoff, S.B.: "Electrocardiographic Effects of Probucol. A Controlled Prospective Clinical Trial." Eur J Clin Pharmacol, 26:735-739, 1984. 61. Dujovne, C.A.: "The High Risk Cardiovascular Patient." J KS Med Soc, 86(1): 17-18, & 31, Jan. 62. Zucker, M.L., Trowbridge, C., Woodroof, J., Chernoff, S., Reynoso, L. and Dujovne, C.A.: "Low- vs. High-dose Aspirin. Effects on Platelet Function in Hyperlipoproteinemic and Normal Subjects." Arch Intern Med, 146:921-925, May 1986. 63. Jackson, B., Dujovne, C.A., DeCoursey, S., Beyer, P., Brown, E.F. and Hassanein, K.: "Methods to Assess Relative Reliability of Diet Records: Minimum records for Monitoring Lipid and Caloric Intake." J Am Diet Assoc, 86(11): 1531-1535, Nov. 1986. 65. Zucker, M.L., Trowbridge, C., Krehbiel, P., Jackson, B., Chernoff, S.B. and Dujovne, C.A.: "Platelet Function in Hypercholesterolemics Before and After Hypolipidemic Drug Therapy." Haemostasis, 16:57-64, 1986. 66. Dujovne, C.A.: "Guidelines for the Use of Cholesterol-Lowering Medications." Intern Med Specialist, 7(9): 101-106, Sept. 1986. 67. Dujovne, C.A., Krehbiel, P. and Chernoff, S.B.: "Controlled Studies of the Efficacy and Safety of Combined Probucol-Colestipol Therapy." Am J Cardiol, 57:36H-42H, June 1986. 68. Salhab, A.S. and Dujovne, C.A.: "Toxicity of Promazine and Chlorpromazine to Isolated Rat Hepatocytes and Its Modification by Liposome Entrapment." Pharmacology, 33:311-321, 1986. 69. Brown, W.V., Dujovne, C.A., Farquhar, J.W., Feldman, E.B., Grundy, S.M., Knopp, R.H., Lasser, N.L., Mellies, M.J., Palmer, R.H., Samuel, P., Schonfeld, G. and Superko, H.R.: "Effects of Fenofibrate on Plasma Lipids - Double-Blind, Multicenter Study in Patients with Type IIA or IIB Hyperlipidemia." Arterioscl, 6(6): 670-678, Nov-Dec 1986. 70. Dujovne, C.A.: "Clinician's Approach to Detection and Therapy of Dyslipidemia." Cardiovascular 71. Knopp, R.H., Brown, W.V., Dujovne, C.A., Farquhar, J.W., Feldman, E.B., Goldberg, A.C., Grundy, S.M., Lasser, N.L., Mellies, M.J., Palmer, R.H., Samuel, P., Schonfeld, G. and Superko, H.R.: "Effects of Fenofibrate on Plasma Lipoproteins in Hypercholesterol- emia and Combined Hyperlipidemia." Am J Med, 83(5B): 50-59, Nov. 1987. 72. Harris, W.S., Zucker, M.L. and Dujovne, C.A.: "O-3 Fatty Acids in Hypertriglyceridemic Patients: Triglycerides vs. Methyl Esters 1-3." Am J Clin Nutr, 48:992-997, 1988. 73. Zucker, M.L., Bilyeu, D.S., Helmkamp, G.M., Harris, W.S. and Dujovne, C.A.: "Effects of Dietary Fish Oil on Platelet Function and Plasma Lipids in Hyperlipoproteinemic and Normal Subjects." Atheroscl, 73:13-22, 1988. 74. Dujovne, C.A. and Harris, W.S.: "Approach to Diagnosis and Treatment of Subjects at Risk for Dyslipidemia-Induced, Atherosclerotic Cardiovascular Disease." Practical Cardiol, Special Issue:24-30, May 1988. 75. Lovastatin Study Group III: "A Multicenter Comparison of Lovastatin and Cholesty- ramine Therapy for Severe Primary Hypercholesterolemia." JAMA, 260(3): 359-366, July 1988. 76. Harris, W.S., Dujovne, C.A., Zucker, M. and Johnson, B.: "Effects of a Low Saturated Fat, Low Cholesterol Fish Oil Supplement in Hypertriglyceridemic Patients - A Placebo Controlled Trial." Ann Intern Med, 109(6): 465-470, Sept. 1988. 77. Altman, R., Scazziota, A. and Dujovne, C.A.: "Diltiazem Potentiates the Inhibitory Effect of Aspirin on Platelet Aggregation." Clin Pharmacol Thera, 44(3): 320-325, Sept. 1988. 78. Dujovne, C.A.: "The Lipid-Hypertension Treatment Connection." Perspectives in Lipid Disorders, 79. Sirtori, C.R., Johnson, B., Vaccarino, V., Montanari, G., Cremoncini, M., Gianfranceschi, G., Sirtori, M. and Dujovne, C.A.: "Lipid Effects of Celiprolol, A New Cardioselective "-blocker, Versus Propranolol." Clin Pharmacol Ther, 45:617-626, 1989. 80. Sztern, M. and Dujovne, C.A.: "The European (EAS) and the American (NCEP) Cholesterol Guidelines: Are They Still Adequate?" Postgrad Med J, 65 (1):S2-S5, 1989. 81. Harris, W.S. and Dujovne, C.A.: "Management of Hypercholesterolemia." Current Opinion in 82. Dujovne, C.A. and Harris, W.S.: "The Role of Fish Oils in the Treatment of Hyperlipid- emia." Modern Medicine, 57(8): 69-79, August 1989. 83. Dujovne, C.A. and Harris, W.S.: "The Pharmacological Treatment of Dyslipidemia." In Annu Rev Pharmacol Toxicol, 29:265-288, 1989. 84. Havel, R.J., Davignon, J., Dujovne, C.A., Gregg, R., Hunninghake, D.B., et al: “Workshop VI, Drug Therapy.” Circulation, 80(3): 744-748, September 1989. 85. Harris, W.S., Silveira, S. and Dujovne, C.A.: "The Combined Effects of O-3 Fatty Acids and Aspirin on Hemostatic Parameters in Man." Thrombosis Research, 57:517-526, 1990. 86. Dujovne, C.A. and Harris, W.S.: Invited Editorial - "Variabilities in Serum Lipid Measure- ments: Do They Impede Proper Diagnosis and Treatment of Dyslipidemia?" Arch Intern Med, 150(8): 1583-1585, August 1990. 87. Lovastatin Study Group IV: "A Multicenter Comparison of Lovastatin and Probucol for Treatment of Severe Primary Hypercholesterolemia," Am J Cardiol, 66:22B-30B, Sept. 1990. 88. Harris, W.S., Dujovne, C.A., von Bergmann, K., Neal, J., Akester, J., Windsor, S.L., Greene, D. and Look, Z.: "Effects of the ACAT Inhibitor CL 277,082 on Cholesterol Metabolism in Humans." Clin Pharmacol Ther, 48(2): 189-194, Aug. 1990. 89. Bradford, R.H., Shear, C.L., Chremos, A.N., Dujovne, C.A., Franklin, F.A., Hesney, M., Higgins, J., Langendorfer, A., Pool, J.L., Schnaper, H. and Stephenson, W.P.: "Expanded Clinical Evaluation of Lovastatin (EXCEL) Study: Design and Patient Characteristics of a Double-Blind, Placebo-Controlled Study in Patients with Moderate Hypercholesterolemia," Am J Cardiol, 66:44B-55B, 1990. 90. Harris, W.S., Windsor, S.L. and Dujovne, C.A.: "Effects of Four Doses of n-3 Fatty Acids Given to Hyperlipidemic Patients for Six Months,” J Am Coll Nutr, Vol. 10(3):220-227, 1991. 91. Bradford, R.H., Shear, C.L., Chremos, A.N., Dujovne, C.A., Downton, M., Franklin, F.A., Gould, L., Hesney, M., Higgins, J., Hurley, D.P., Langendorfer, A, Nash, D.T., Pool, J.L., and Schnaper, H.: "Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results. I. Efficacy in Modifying Plasma Lipoproteins and Adverse Event Profile in 8245 Patients with Moderate Hypercholesterolemia." Arch Intern Med, 151:43-49, Jan. 1991. 92. Dujovne, C.A.: "Drug Intervention Trials in Dyslipidemia: The Past and the Future." Clin Cardiol, 93. Dujovne, C.A., Chremos, A.N., Pool, J.L., Schnaper, H., Bradford, R.H., Shear, C.L., Higgins, J., Downton, M., Franklin, F.A., Nash, D.T., Gould, A.L., Langendorfer, A.: "Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results: IV. Additional Perspectives on the Tolerability of Lovastatin." Am J Med, 91(1B):25S-30S, July 1991. 94. Bradford, R.H., Shear, C.L., Chremos, A.N., Franklin, F.A., Nash, D.T., Hurley, D.P., Dujovne, C.A., Pool, J.L., Schnaper, H., Hesney, M., Langendorfer, A.: "Expanded Clinical Evaluation of Lovastatin Study Results: III. Efficacy in Modifying Lipoproteins and Implications for Managing Patients with Moderate Hypercholesterolemia." Am J Med, 91(1B):18S-24S, July 1991. 95. Pool, J.L., Shear, C.L., Downton, M., Schnaper, H., Stinnet, S., Dujovne, C.A., Chremos, A.N.: "Lovastatin and Coadministered Antihypertensive/Cardiovascular Agents." Hypertension, 1(3):242-248, March, 1992. 96. Bays, H.E., Dujovne, C.A.: "Drug Therapy for Hyperlipidemia - When Reducing Cardiovascular Risk is a Priority." Hyperlipidemia (Postgraduate Medicine), 91(5): 162-193, April 1992. 97. Dujovne, V.F., Houston, B.K., and Dujovne, C.A.: "Type A Behavior, Anger Expression, and Plasma Lipid Levels: A Preliminary Study." Coronary Artery Disease, 3:1171-1176, Dec. 1992. 98. Bays, H.E., Dujovne, C.A., Lansing, A.M.: "Drug Treatment of Dyslipidemias: Practical Guidelines for the Primary Care Physician." Heart Disease and Stroke, 1:357-365, 1992. 99. Hunninghake, D.B., Stein, E.A., Dujovne, C.A., Harris, W.S., Feldman, E.B., Miller, V.T., Tobert, J.A., Laskarzewski, P.M., Quiter, E., Held, J., Taylor, A.M., Hopper, S., Leonard, S.B., Brewer, B.K.: "The Efficacy of Intensive Dietary Therapy Alone or Combined with Lovastatin in Outpatients with Hypercholesterolemia." NEJM, 328(17):1213-1219, April 29, 1993. 100. Lovastatin Study Groups I, II, III & IV: "Lovastatin 5-Year Safety and Efficacy Study." Arch Int Med, 153(9): 1079-1087, May 10, 1993. 101. Rader, Daniel J., Schaefer, Juergen R., Lohse, Peter, Ikewaki, Katsunori, Thomas, Fairwell, Harris, William A., Zech, Loren A., Dujovne, Carlos A., and Brewer, H. Bryan, Jr.: "Increased Production of Apolipoprotein A-I Associated with Elevated Plasma Levels of High-Density Lipoproteins, Apolipoprotein A-I, and Lipoprotein A-I in a Patient with Familial Hyperalphalipoproteinemia," Metabolism, 42(11): 1429-1434, Nov. 1993. 102. Dujovne, C.A., Eff, J., Ferraro, L., Goldstein, R., Gotto, A., Hall, N., Harris, W., Held, S.J., Herd, A., Hunninghake, D., Johnson, B., Sztern, M.: "Effects of Atenolol Versus Celiprolol on Serum Lipids and Blood Pressure in Hyperlipidemic and Hypertensive Subjects: A Double-Blind, Dietary Constancy-Monitored Multicenter Trial." Am J Card, 72:1131-1136, Nov. 15, 1993. 103. Pravastatin Multicenter Study Group II: "Comparative Efficacy and Safety of Pravastatin and Cholestyramine Alone and Combined in Patients with Hypercholesterolemia." Arch Int Med, 153:1321-1329, June 14, 1993. 104. Bays, H.E. and Dujovne, C.A.: "Antioxidants in the Treatment and Prevention of Atherosclerotic Cardiovascular Disease." Clin Invest Arteriosclerosis, 5(4): 166-175, 1993. 105. Bays, H.E., Dujovne, C.A., and Mays, B.: "Elevated Lipoprotein(a) Blood Levels as the Single Treatable Atherosclerotic Risk Factor in Patients with Coronary Artery Disease," Kentucky Med, pp. 498-500, Nov. 1993. 106. Bays, H.E. and Dujovne, C.A.: "Antioxidants in Clinical Practice." Choices Card, 8(1): 6-8, 1993. 107. Bays, H.E. and Dujovne, C.A.: "Management of Multiple Cardiovascular Risk Factors in Primary Care," Res Staff Physician, 40(4): 11-28, April 1994. 108. Dujovne, C.A. and Davidson, M.H.: "Fluvastatin Administration at Bedtime Versus with the Evening Meal: A Multicenter Comparison of Bioavailability, Safety and Efficacy." Am J Med, 96(6A):37-40, June 6, 1994. 109. Dujovne, C.A., Harris, W.S., Gerrond, L.L., Fan, J. and Muzio, F.: "Comparison of Effects of Probucol Versus Vitamin E on Ex Vivo Oxidation Susceptibility of Lipoproteins in Hyperlipoproteinemia," Am J Card, 74:38-42, July 1, 1994. 110. Illingworth, D.R., Stein, E.A, Mitchell, Y.B., Dujovne, C.A., Frost, P.H, Knopp, R.H., Tun, P., Zupkis, R.V., Greguski, R.A., "Comparative Effects of Lovastatin and Niacin in Primary Hypercholesterolemia: A Prospective Trial." Arch Int Med, 154:1586-1595, July 25, 1994. 111. Bradford, R.H., Shear, C.L., Chremos, A.N., Dujovne, C.A., Franklin, F.A., Grillo, R.B., Higgins, J., Langendorfer, A., Nash, D.T., Pool, J.L. and Schnaper, H., "Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results: Two-Year Efficacy and Safety Follow-up," Am J Card, 74:667-673, October 1, 1994. 112. Insull, W., Black, D., Dujovne, C.A., Hosking, J.D., Hunninghake, D., et al, “Efficacy and Safety of Once-Daily vs. Twice-Daily Dosing With Fluvastatin, a Synthetic Reductase Inhibitor, in Primary Hypercholesterolemia.” Arch Intern Med, 154:2449-2455, November 14, 1994. 113. Bays, H.E., and Dujovne, C.A., “Drugs for Treatment of Patients With High Cholesterol Blood Levels and Other Dyslipidemias.” Progress in Drug Research, 43, 1994. 114. Lozada, A., and Dujovne, C.A., “Drug Interactions With Fibric Acids.” Pharmac. Ther., 115. Schrott, H.G., Stein, E.A., Dujovne, C.A., Davidson, M.H., Goris, G.B., Oliphant, T.H., Phillips, J.C., and Shawaryn, G.G.: "Enhanced Low-Density Lipoprotein Cholesterol Reduction and Cost- Effectiveness by Low-Dose Colestipol Plus Lovastatin Combination Therapy," Am J Card, 75:34-39, Jan. 1, 1995. 116. Insull, W., Davidson, M.H., Demke, D.M., Dujovne, C.A., Eckert, S.M., Ginsberg, D., Goldberg, A.C., Hodis, H.N., Hughes, T.A., Kane, J.P., Oliphant, T.H., Pitt, W.A., Schrott, H.G., Sprecher, D.L., and Zavoral, J.H.: "The Effects of Colestipol Tablets Compared with Colestipol Granules on Plasma Cholesterol and Other Lipids in Moderately Hypercholesterolemic Patients," Atherosclerosis, 112:223-235, 1995. 117. Harris, W.S., Held, S.J., and Dujovne, C.A.: "Comparison of Two Scoring Systems Used to Monitor Diets in Outpatient Clinical Trials," J Cardiovascular Risk, 2:359-365, 1995.
118. Illingworth, D.R., Stein, E.A., Knopp, R.H., Hunninghake, D.B., Davidson, M.H., Dujovne, C.A., Miller, V.T., Tobert, J.A., Laskarzewski, P.M., Isaacsohn, J.L., Bacon, S.P., and Tate, A.C.: "A Randomized Multicenter Trial Comparing the Efficacy of Simvastatin and Fluvastatin," J Cardiovasc Pharmacol Therapeut, 1(1):23-30, 1996. 119. Dujovne, C.A. and Moriarty, P.M.: “Clinical Pharmacologic Concepts for the Rational Selection and Use of Drugs for the Management of Dyslipidemia, “ Clin. Therapeut., 18(3):392-410, 1996. 120. Stein, E.A., Davidson, M.H., Dujovne, C.A., Hunninghake, D.B., Goldberg, R.B., Illingworth, D.R., Knopp, R.H., Miller, V.T., Frost, P., Isaaxsohn, J.L., Mitchel, Y.B., Melino, M.R., Shapiro, D., and Tobert, J.A.: “Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial,” J Cardiovasc Pharmacol Therapeut, 1(2): 107-116, 1996. 121. Davidson, M. H., Stein, E.A., Dujovne, C.A., Hunninghake, D.B., Weiss, S.R., Knopp, R.H., Illingworth, D.R., Mitchell, Y.B., Melino, M.R., Zupkis, R.V., Dobrinska, M.R., Amin, R.D., Tobert, J.A.: “The Efficacy And Six-Week Tolerability Of Simvastatin 80 And 160 Mg/Day,” Am J Card, 79:38-42, 1997. 122. Dujovne, C.A. “The Clinical-Therapeutic Implications of the Scandinavian Simvastatin Survival Study,” Am J Card, 79:1387-1388, 1997. 123. Harris, W.S., Dujovne, C.A., Windsor, S.L., Colle Gerrond, L.L., Newton, F.A., and Gelfand, R.A.: “Inhibiting Cholesterol Absorption with CP-88, 818 ("-tigogenin cellobioside; tigueside): Studies in Normal and Hyperlipidemic Subjects,” J Cardiovasc Pharma, 30:55-60, 1997. 124. Dujovne, C.A. “New Lipid Lowering Drugs and New Effects of Old Drugs,” Current Opinion of 125. Dujovne, C.A., Guest Editor: “Guidelines For Clinical Evaluation, Development, and Regulation of Lipid-Acting Anti-Atherosclerosis Agents,” Am J Card, 81:1-94, 1998. 126. Stein, E.A., Davidson, M.H., Dobs, A.S., Schrott, H., Dujovne, C.A., Bays, H., Weiss, S.R., Melino, M.R., Stepanavage, M.E., Mitchel, Y.B.: “Efficacy and Safety of Simvastatin 80mg/day in Hypercholesterolemic Patients,” Am J Card, 82:311-316, 1998. 127. Bays, H.E., and Dujovne, C.A.: “Drug Interactions of Lipid-Altering Drugs,” Drug Safety, 19(5): 128. Anderson, J.W., Pi-Sunyer, F.X., Danforth, E., Dujovne, C.A., Greenway, F., Hill, J.O., Lucas, C.P., O’Neil, P.M., Smith, D.K.: “Clinical Trial Design for Obesity Agents: A Workshop Report,” Obesity Research, 6(4): 311-5, 1998. 129. Bays, H.E., and Dujovne, C.A.: “Lipid-Altering Drugs in Development,” Drugs in R&D, 1(6): 130. Guyton, J.R., Dujovne, C.A., Illingworth, D.R.: “Dual Hepatic Metabolism of Cerivastatin- - Clarifications,” Am J Card, 84(4):497, 1999 Aug 15. 131. Dujovne, C.A.: “Middle-aged Men at High Risk of Cardiovascular Disease: the West of Scotland Coronary Prevention Study,” Am J Med, 107(2A): 34S-35S, 1999 Aug 23. 132. Stein, E.A., Illingworth, D.R., Kwiterovich, Jr., P.O., Liacouras, C.A., Siimes, M.A., Jacobson, M.S., Brewster, T.G., Hopkins, P., Davidson, M., Graham, K., Arensman, F., Knopp, R.H., Dujovne, C., Williams, C.L., Isaacsohn, J.L., Jacobson, C.A., Laskarzewski, P.M., Ames, S.m Gormley, G.J.: “Efficacy and Safety of Lovastatin in Adolescent Males with Heterozygous Familial Hypercholesterolemia: a ramdomized controlled trial,” JAMA, 281(2): 137-44, 1999 Jan 13. 133. Knopp, R.H., Superko, H.R., Davidson, M., Insull, W., Dujovne, C.A., Kwiterovich, P.O., Zavoral, J.H., Graham, K., O’Connor, R.R., Edelman, D.A.: “Long-term Blood Cholesterol-lowering Effects of a Dietary Fiber Supplement,” Am J Prev Med, 17(1): 18- 23, 1999 Jul. 134. Hunninghake, D., Dujovne, C., Stein, E., Insull, W., Ripa, S., Shan, M.: “The 0.4 mg Dose of Cerivastatin: Comparative Safety and Efficacy of Cerivastatin 0.3 mg versus Fluvastatin 40 mg,” Pharmacotherapy 1999: 19: 1194. 135. Insull, Jr., W., Isaacsohn, J., Kwiterovich, P., Ma, P., Brazg, R., Dujovne, C., Shan, M., Shugrue- Crowley, E., Ripa, S., Tota, R. for the Cerivastatin Study Group: “Safety and Efficacy of Cerivastatin 0.8 mg Daily for 8 Weeks: the Pivotal Placebo-controlled Clinical Trial,” Pharmacotherapy 1999: 19: 1196 136. Dujovne, C., Knopp, R., Kwiterovich, P.,m. Hunninghake, D., McBride, T., Poland, M.: “Randomized Comparison of the Efficacy and Safety of Cerivastatin and Pravastatin in 1030 Hypercholesterolemic Patients,” Mayo Clinic Proceedings 2000: 75: 1124-1132. 137. Dujovne, C.A., Harris, W.S., Altman, R., Overhiser, R.W., Black, D.M.: “Effect of Atorvastatin on Hemorheologic-Hemostatic Parameters and Serum Fibrinogen Levels in Hyperlipidemic Patients,” Am J Card, 2000: 85:350-353. 138. Pfuetze, K.D., Dujovne, C.A.:”Probucol,” Current Atherosclerosis Reports 2000: 2: 47- 57. 139. Insull, Jr., W., Isaacsohn, J., Kwiterovich, P., Ma, P., Brazg, R., Dujovne, C., Shan, M., Shugrue- Crowley, E., Ripa, S., Tota, R. for the Cerivastatin Study Group: “Efficacy and Safety of Cerivastatin 0.8 mg in Patients with Hypercholesterolemia: the Pivotal Placebo-controlled Clinical Trial,” J of International Med Research, 2000; 28: 47-68. 140. Kastelein, J.J., Isaacsohn, J.L., Ose, L., Hunnighake, D.B., Frohlich, J., Davidson, M.H., Habib, R., Dujovne, C.A., Crouse, J.R., Lui, M., Melino, M.R., O’Grady, L., Mercuri, M., Mitchel, Y.B.: “Comparison and Effects of Simvastatin versus Atorvastatin on High- density Lipoprotein Cholesterol and Apoliprotein A-I Levels,” Am J Card, 86(2): 221-3, 2000 Jul 15. 141. Isaacsohn, J., Insull, W., Kwiterovich, P., Dujovne, C., et al.: “Long-term Efficacy and Safety of Cerivastatin 0.8 mg and 0.4 mg vs. Pravastatin 40 mg,” Pharmacotherapy 2000: 20: 1235. 142. Dujovne, C.A., Bays, H., Davidson, M.H., Knopp, R., Hunninghake, D.B., Stein, M.A., Goldberg, A.C., Jones, P., Lipka, L.J., Cuffie-Jackson, C.: “Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a Multicenter Dose-Ranging Study,” J of Clin Pharm 2001;41:70-78. 143. Insull, W., Koren, M., Davignon, J., Sprecher D., Schrott, H., Keilson, L.M., Brown, A.S., Dujovne, C.A., Davidson M. H., McLain R., Heinonen T.: “Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia,” Atheroscelerosis 157 (2001) 137-144. 144. Gallup, E., Dujovne, C.,: “New pharmacological agents under clinical investigation for treating disorders of lipoprotein regulation leading to atherosclerosis,” 2001 Ashley Publications Ltd.ISSN 1354-3784. 145. Dujovne, C.A., Zavoral, J.H., Rowe, E. Mendel, C. M., for the Sibutramine Study Group Overland Park, Kan, Edina, Minn, and Mount Olive, NJ: “Effects of sibutramine on body weight and serum lipids: A double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia,” Amer. Heart J. 2001;142:489-97. 146. Bays, H.E., Moore, P.B., Drehobl, M.A., Rosenblatt, S., Toth, P.D., Dujovne, C.A., Knopp, R.H., Lipka, L.J., LeBeaut, A.P., Yang, B., Mellars, L.E., Cuffie-Jackson, C., Veltri, E.P., for the Exetimible Study Group: “Effectiveness and Tolerability of Exetimible in Patients with Primary Hypercholesterolemia: Pooled Analysis of Two Phase II Studies,” Clinical Therapeutics Vol. 23, NO. 8, 2001: 1209-1230 147. Dujovne, C.A., Tonkin, A. : “Ethical, medical and legal issues for the use of placebos in future lipid intervention trials.” Current Opinion in Lipidology Vol. 12, No. 6, December 2001 148. Dujovne, C.A.,”Side Effects of Statins: Hepatitus Versus “Transaminitis”—Myositis vs ‘CPKitis’” The American Jounral of Cardiology, Vol. 89, 1411-1413June 15; 2002 149. Bays, H., Dujovne, C.A., “Pharmacotherapy of Obesity Currently Marketed and Upcoming Agents.” Am J Cardiovasc Drugs 2002: 2 (4) 245-253 150. Bays, H., Dujovne, C.A., “Anti-obesity drug development.” Expert Opin. Investig. Drugs (2002) 151. Dujovne, C.A., Ettinger, M., McNeer, F., Lipka, L., LeBeaut, A., Suresh, R., Yang, B., Veltri, E., for the Ezetimibe Study Group, “Efficacy and Safety of a Potent New Selective Cholesterol Absorption Inhibitor, Ezetimibe in Patients With Primary Hypercholesterolemia.” The American Journal of Cardiology, Vol. 90 November 15, 2002, 1091-1097 152. Isaacsohn, J., Hunnighake, D., Schrott, H., Dujovne, C.A., Knopp, R., Weiss, S., Bays, H., Crouse, J.R. III, Davidson, M.H., Keilson, L.M., McKenney, J., Korenman, S.G., Dobs, A.S., Stein, E., Krauss, R.M., Maccubbin, D., Cho, M., Plotkin, D.J., Mitchel, Y.B.; “Effects of Simvastatin, an HMG-CoA Reductase Inhibitor, in Patients with Hypertriglyceridemia.” Clin. Cardiol. 26, 18-24 (2003) 153. Knopp, R.H., Dujovne, C.A., Le Beaut, A., Lipka, L.J., Suresh, R., Veltry. E.P. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolemia: a pooled analysis from two controlled phase III clinical studies. Int. J. Clin. Pract. 57:363-8, 2003. 154. Bays, H., Dujovne, C.A., McGovern, M., White, T.E., Kashyap, M.L., Hutcheson, A.G., Crouse, J.R., “Comparison of Once-Daily, Niacin Extended-Release/Lovastatin With Standard Doses of Atorvastatin and Simvastatin (The Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation (ADVOCATE)).” The American Journal of Cardiology, Vol. 91 March 15, 2003, 667-672 155. Dujovne, C. A. “Treatment of Familial Hypercholesterolemia and Other Genetic Dyslipidemias. Current Treatment Options.” Cardiovascular Med. 6(4): 269-278, 2004. 156. Bays, H., Dujovne, C.A., “Colesevelam HCI: a non-systemic lipid-altering drug” Expert Opin. Pharmacother. (2003) 4(5): 779-790 157. Bays, H., McKenney, J., Dujovne, C.A., Schrott, H., Zema, M., Nyberg, J., and MacDougall, D., for the Gemcabene Study Group, “Effectiveness and Tolerability of a New Lipid-Altering Agent, Gemcabene, in Patients With Low Levels of High-Density 158. Lipoprotein Cholesterol” The American Journal of Cardiology, Vol. 92 September 1, 2003, 159. Dujovne, C.A., “Treatment of Familial Hypercholesterolemia and Other Genetic Dyslipidemias.” Current Treatment Options in Cardiovascular Medicine, 2004, 6:269- 278 160. Dujovne, C.A., “Future Lipidology.” Clinical-Pharmacological Implications of Over-the- Counter Statins, 2006, Vol. 1, No. 1, Pages 17-24. 161. Bays, H.; Dujovne, C.A.; “Adiposopathy is a More Rational Treatment Target for Metabolic Disease than Obesity Alone,” Current Atherosclerosis Reports, 8:144-156, 2006. 162. Mays M. E., Dujovne C. A. “Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia?” Current Atherosclerosis Reports, 10(1): 45-52, 2008. 163. Dujovne, C.A., Williams, C.D, and Ito, M.K. “What combination therapy with a statin, if any, would you recommend?” Current Atherosclerosis Report; 13:12, 2011. BOOK EDITOR/AUTHOR
Dujovne, C.A., Editor: "A Change of Heart: Steps to Healthy Eating."
Kansas Foundation for Clinical Pharmacology, Publisher, 1st Edition, 1990; 2nd Edition, 1993; 3rd BOOK CHAPTERS
Dujovne, C.A. and Azarnoff, D.L.: "Clinical Complications of Corticosteroid Therapy: A Selected Review." In Steroid Therapy, Azarnoff, D.L. (ed.); Saunders, W.B.; Philadelphia, pp. 27-41, 1975. Dujovne, C.A.: "Findings and Interpretation of Changes in Serum Alkaline Phosphatase, Creatine Phosphokinase, Bilirubin and Liver Scanning in Patients Receiving Hypolipidemic Drugs." In Drugs Affecting Lipid Metabolism, Fumagalli, R., Kritchevsky, D. and Paoletti, R. (ed.); Elsevier/North-Holland Biomedical Press, pp. 293-300, 1980. Dujovne, C.A.: "Differentiation of Toxic from Spurious Abnormalities after Drug Administration in Man in Drug Effect on Laboratory Test Results." In Developments in Clinical Biochemistry, vol. 2, Siest, G. (ed.); Martinus Nijhoff Publishers, The Hague, Netherlands, pp. 214-220, 1980.
Dujovne, C.A.: Vol. I, "Pharmacology of the Esophagus," pp 101-103; 38, "Clinical Pharmacology of Drugs Used for Treatment of Diseases of the Stomach," pp. 289-295; "Pharmacology of the Small Intestine," pp 481-482; "Pharmacology of the Colon," pp. 683-689. Vol. II, "Pharmacology of the Liver;" and "Medical Treatment of Gallstones," in Sections III and IV. In Treatise of Gastroenterology and Hepatology, Cantor, D.S. and Grossman, R.J. (eds.); Salvat, Barcelona, Spain. Dujovne, C.A.: "Relationship Among Lipid Disorders, Coagulation and Thrombosis," and "The Actions of Hypolipidemic Drugs." Proceedings of the Symposium on Lipids, Platelets and Thrombosis, pp. 39-47. Buenos Aires, Argentina, 1982. Dujovne, C.A.: "The Clinical Pharmacology of Glucocorticoids." Proceedings of the First InterAmerican Congress of Clinical Pharmacology and Therapeutics, Caracas, Venezuela, October 10-15, 1982. In Excerpta Medica, Velasco, M. (ed.); Elsevier Science Publishing Company, Amsterdam, pp. 212-223, 1982. Dujovne, C.A.: "Effects of Gastrointestinal and Hepatic Pathology on Human Drug Responses." In Recent Advances in Clinical Therapeutics, vol. 2, Yetiv, J.Z. and Bianchine, J.R. (ed.); New York Academic Press, New York Grune and Stratton, Inc., pp. 219-228, 1983. Dujovne, C.A. and Krehbiel, P.: "Considerations for Controlled Clinical Testing of Safety and Efficacy of New Hypolipidemic Drugs." Proceedings of the IX International Symposium on "Drugs Affecting Lipid Metabolism," Florence, Italy, Oct. 1986, Paoletti, R. (ed.); Springer-Verlag Berlin, pp. 136-141, 1987. 10. Dujovne,C.A.: "Drugs for Treatment of Hyperlipoproteinemias." In Practical Drug Therapy, 2nd edition, Wang, R.I.H. (ed.); Medstream Press, Inc., Milwaukee, WI, pp. 169-180, 1987. 11. 10.Dujovne, C.A.: "Cholestyramine." In Therapeutic Drugs, A Clinical Pharmacopoeia, Dollery, C.T. (ed.); Churchill Livingstone, New York, 1:C225-C228, 1991.
12. 11.Dujovne, C.A.: "Colestipol." In Therapeutic Drugs, A Clinical Pharmacopoeia, Dollery, C.T. (ed.); Churchill Livingstone, New York, 1:C342-C345, 1991.
13. 12.Dujovne, C.A.: "Probucol." In Therapeutic Drugs, A Clinical Pharmacopoeia, Dollery, C.T. (ed.); Churchill Livingstone, New York, 2:P222-P225, 1991.
14. 13.Lozada, A. and Dujovne, C.A.: "Drug Interactions with Fibric Acids." In Pharmac Ther, Vol. 63, Sirtori, C.R. (ed.); Elsevier Science Ltd., Great Britain, pp. 163-176, 1994.
15. 14.Bays, H.E. and Dujovne, C.A.: "Drugs for Treatment of Patients with High Cholesterol Blood Levels and Other Dyslipidemias." In Progress in Drug Research, Jucker, E. (ed.); Birkhäuser Verlag, Basel, Switzerland; Volume 43, pp. 9-41, 1994.
16. 15.Dujovne, C.A., Harris, W.S., Gelfand, R.A., Morehouse, L.A., McCarthy, P.A., Chandler, C.E., DeNinno, M.P., Harwood Jr., H.J., Newton, F.A. and Shear, C.L.: "Investigations of the Effects of Synthetic Saponins on Cholesterol Absorption and Serum Cholesterol Levels." In Atherosclerosis X, Proc. of 10th International Symposium on Atherosclerosis, Montreal, Canada, Oct. 9-14, 1994, Woodford, F.P., Davignon, J. and Sniderman, A. (eds.); Elsevier, Amsterdam, pp. 298-306, 1995.
17. 16.Dujovne, C.A., Krehbiel, P.E., Harris, W.S. and Held, S.J.: "Phase II Trials with Lipid-Acting Drugs." In Handbook of Phase I/II Clinical Drug Trials, O'Grady, J. and Joubert, P. (eds.); CRC Press, Inc., Hampshire, England; pp. 463-473, 1997.


Nordic Section of the Regional Science Association Submitted to Parallel 2: Networks, Innovations and Infrastructure Robert Sörensson, CERUM, Umeå University, SE-901 87 Umeå, Sweden Are MAR, Jacobs and Porter externalities less important for multi-plant firms than single plant firms? In the literature treating endogenous growth models, human capital accumulation and knowledge spillov

2007-comunicat-londres cat.rtf

Comunicat de Londres Cap a l'Espai europeu d'educació superior: responent als reptes d'un món globalitzat I. Prefaci 1.1 Els ministres responsables de l'educació superior dels països que participen en el Procés de Bolonya, ens hem reunit a Londres per verificar els progressos des de la reunió celebrada a 1.2 D'acord amb els criteris acordats perquè un país s'incorpori

Copyright © 2018 Medical Abstracts